Key Points
- Insider Alexander Schuth sold 2,768 Denali Therapeutics shares for $64,881.92 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 0.98% to 278,995 shares.
- Denali shares opened at $22.80, near their $12.58–$27.30 52-week range. The company reported a quarterly loss of $0.68 per share, missing estimates, despite revenue of $3.60 million exceeding expectations.
- Analysts maintain a “Moderate Buy” consensus, with an average price target of $35.85, while institutional investors own 92.92% of the stock.
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander Schuth sold 2,768 shares of the company's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares of the company's stock, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Denali Therapeutics Trading Down 0.2%
Shares of DNLI stock opened at $22.80 on Friday. The stock has a 50-day simple moving average of $24.50 and a 200 day simple moving average of $21.83. The stock has a market capitalization of $3.64 billion, a P/E ratio of -8.03 and a beta of 1.01. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $27.30. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analysts' expectations of $2.15 million. During the same quarter in the previous year, the business posted ($0.72) EPS. On average, sell-side analysts expect that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.
Institutional Trading of Denali Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its holdings in shares of Denali Therapeutics by 21.7% in the 1st quarter. Bank of America Corp DE now owns 1,134,183 shares of the company's stock valued at $21,776,000 after purchasing an additional 202,039 shares during the period. Great Lakes Advisors LLC purchased a new stake in shares of Denali Therapeutics in the second quarter worth approximately $3,731,000. E. Ohman J or Asset Management AB acquired a new stake in shares of Denali Therapeutics during the second quarter worth approximately $4,115,000. Sei Investments Co. acquired a new stake in shares of Denali Therapeutics during the first quarter worth approximately $1,003,000. Finally, UBS Group AG grew its position in Denali Therapeutics by 19.5% during the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company's stock valued at $39,702,000 after purchasing an additional 392,351 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.
Analyst Ratings Changes
A number of analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Morgan Stanley lifted their price target on shares of Denali Therapeutics from $35.00 to $36.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an "overweight" rating and a $29.00 price target on the stock. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $41.00 price objective on Denali Therapeutics in a research report on Monday, June 22nd. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $35.85.
Check Out Our Latest Stock Report on Denali Therapeutics
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
